Diabetes Mellitus
Conditions
Interventions
Sponsors
First Affiliated Hospital of Harbin Medical University
Eligibility
Sex/Gender
All
Age
20 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. meet the WHO diabetes expert committee formulated diagnostic criteria for diabetes mellitus; 2. after admission by mydriatic fundus angiography (FFA) examination, diagnostic criteria in line with the family of unified national society of Ophthalmology of diabetic retinopathy; 3. 6.5%<HbA1c<10%; 4. Aged 20-75 years old.;Inclusion criteria: 1. meet the WHO diabetes expert committee formulated diagnostic criteria for diabetes mellitus; 2. after admission by mydriatic fundus angiography (FFA) examination, diagnostic criteria in line with the family of unified national society of Ophthalmology of diabetic retinopathy; 3. 6.5%<HbA1c<10%; 4. Aged 20-75 years old.
Exclusion criteria
Exclusion criteria: 1. Type 1 diabetes; 2. renal insufficiency (ALT is greater than or equal to the normal limit of 3 times; 3. GFR<60ml/min/1.73m2; hyperlipidemia; 4. severe cerebrovascular disease; 5. malignant tumor; 6. MDS, leukemia, lymphoma and other hematological diseases; 7. RA, SLE and other rheumatic diseases; other fundus diseases; 8. macular edema; 9. oral DPP IV inhibitors; 10. statins; 11. acute and chronic infection;Exclusion criteria: 1. Type 1 diabetes; 2. renal insufficiency (ALT is greater than or equal to the normal limit of 3 times; 3. GFR<60ml/min/1.73m2; hyperlipidemia; 4. severe cerebrovascular disease; 5. malignant tumor; 6. MDS, leukemia, lymphoma and other hematological diseases; 7. RA, SLE and other rheumatic diseases; other fundus diseases; 8. macular edema; 9. oral DPP IV inhibitors; 10. statins; 11. acute and chronic infection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vasohibin1 SDF-1;;Vasohibin1 SDF-1; | — |
Secondary
| Measure | Time frame |
|---|---|
| Fasting plasma glucose;HbA1c;triglyceride;total cholesterol;Low density lipoprotein;High density lipoprotein;Alanine aminotransferase;Aspartate aminotransferase;total bilirubin;Urine protein;creatinine;Urea nitrogen;Fasting C peptide;Basic information of patients (sex, age, height, weight, body mass index);diabetic duration;systolic pressure;diastolic pressure;Smoking history and drinking history;History of drug use (insulin, antidiabetic drugs, antihypertensive drugs, lipid-lowering drugs);Degree of diabetic retinopathy;;Fasting plasma glucose;HbA1c;triglyceride;total cholesterol;Low density lipoprotein;High density lipoprotein;Alanine aminotransferase;Aspartate aminotransferase;total bilirubin;Urine protein;creatinine;Urea nitrogen;Fasting C peptide;Basic information of patients (sex, age, height, weight, body mass index);diabetic duration;systolic pressure;diastolic pressure;Smoking history and drinking history;History of drug use (insulin, antidiabetic drugs, antihypertensive drugs, lipid-lowering drugs);Degree of diabetic retinopathy; | — |
Countries
China
Contacts
Public ContactZhang Huijuan;Zhang Huijuan ;
Department of Endocrinology, First Affiliated Hospital of Harbin Medical University;Department of Endocrinology, First Affiliated Hospital of Harbin Medical University
Outcome results
None listed